UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K/A

 

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of August 2022

 

Commission File Number: 001-37353

 

BIONDVAX PHARMACEUTICALS LTD.

(Translation of registrant’s name into English)

 

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jerusalem, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Amendment No. 1 to the Report on Form 6-K, originally filed with the Securities and Exchange Commission on August 25, 2022, is being filed solely for the purposes of furnishing unaudited interim condensed consolidated financial statements as of June 30, 2022 and incorporating certain exhibits into registration statements of the registrant.

 

This Report on Form 6-K (including the text under “Second Quarter 2022 Financial Summary” in Exhibit 99.1 and Exhibit 99.2) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-239344) and Form F-3 (File No. 333-240189), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

Exhibit Index

 

Exhibit No.   Description
     
99.1   Press Release dated August 25, 2022
99.2   Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2022

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BiondVax Pharmaceuticals Ltd.
     
Date: August 29, 2022 By: /s/ Amir Reichman
    Amir Reichman
    Chief Executive Officer

 

 

2

 

true --12-31 Q2 2022-06-30 0001611747

Exhibit 99.1

 

 

BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update

 

JERUSALEM, Aug. 25, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its financial results for the quarter ended June 30, 2022 and provided a business update.

Business Update

 

●Development of the NanoAb program is proceeding according to plan. A pilot quantity of the lead NanoAb, a COVID-19 therapy, was manufactured in-house then sent for preclinical inhalation device evaluation and selection of an inhaler for human use.

 

●In September 2022, BiondVax plans to initiate an inhalation proof of concept study with its anti-SARS-COV-2 NanoAbs in COVID-19 infected animals with readout expected in November 2022.

 

●BiondVax currently holds several anti-SARS-COV-2 NanoAb candidates, generated and initially characterized by Max Planck Institute for Multidisciplinary Sciences in Göttingen together with University Medical Center Göttingen and exclusively licensed from Max-Planck-Innovation GmbH, which demonstrated high affinity to and strong neutralization of COVID-19 VoCs including Omicron BA1&2 and will be testing them in the coming months for neutralization of BA2.75 and BA5.

 

●BiondVax received supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for its COVID-19 NanoAb development plans. PEI supported BiondVax’s plan for first-in-human clinical trial to be conducted directly in sick patients as a combined Phase 1/2a, testing both safety and efficacy, thereby shortening BiondVax’s clinical development timelines.

 

●As part of their broader research collaboration with BiondVax, the researchers at Max Planck Institute for Multidisciplinary Sciences in Göttingen and University Medical Center Gottingen have been able to successfully isolate new NanoAbs targeting IL-17A/F and other cytokines, which can be used for treatment of other diseases such as psoriasis, psoriatic arthritis, asthma, and macular degeneration. BiondVax has an exclusive option for an exclusive license to further develop and commercialize these drug candidates.

 

Second Quarter 2022 Financial Summary

 

Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.5 (NIS/$US), the rate as of the close of business on June 30, 2022.

 

●R&D expenses for the three months ended June 30, 2022 were NIS 6.5 million ($1.85 million) compared to NIS 1.9 million for the three months ended June 30, 2021. Total R&D expenses for the six months ended June 30, 2022 were NIS 10.1 million ($2.9 million) compared to NIS 4.6 million for the six months ended June 30, 2021. These increases were primarily due to drug development activities related to the new COVID-19 NanoAb program licensed from Max-Planck-Innovation GmbH in December 2021.

 

 

 

 

●Marketing, general and administrative expenses for the three months ended June 30, 2022 were NIS 4.3 million ($1.2 million) compared to NIS 7.0 million for the three months ended June 30, 2021. Total marketing, general and administrative expenses for the six months ended June 30, 2022 were NIS 8.9 million ($2.5 million) compared to NIS 11 million for the six months ended June 30, 2021. These decreases were primarily due to salaries and related expenses of NIS 1.2 million and share based payment of NIS 1 million.

 

●Financial expenses for the three months ended June 30, 2022 were NIS 2.1 million ($0.6 million) compared to NIS 3.0 million for the three months ended June 30, 2021. Financial expenses for the six months ended June 30, 2022 were NIS 3.2 million ($1 million) compared to NIS 4.5 million for the six months ended June 30, 2021. These decreases were primarily due to currency exchange differences and EIB loan financial expenses.

 

●Total operating expenses for the three months ended June 30, 2022 were NIS 10.8 million ($3.1 million) compared to NIS 8.9 million for the three months ended June 30, 2021. Total operating expenses for the six months ended June 30, 2022 were NIS 19 million ($5.5 million) compared to NIS 15.6 million for the six months ended June 30, 2021. 

 

●Net loss for the for the three months ended June 30, 2022 was NIS 12.9 million ($3.7 million) compared to NIS 12.0 million for the three months ended June 30, 2021. Net loss for the six months ended June 30, 2022 was NIS 22.3 million ($6.4 million) compared to NIS 20.2 million for the six months ended June 30, 2021. These increases were primarily due to an increase in R&D expenses, offset by a decrease in marketing, general and administrative expenses as described above.

 

As of June 30, 2022, BiondVax had cash and cash equivalents of NIS 39.5 million ($11.3 million) compared to NIS 54.0 million as of December 31, 2021.

 

Unaudited second quarter financial results will be submitted to the Securities and Exchange Commission. A summary is included in the tables below.

 

About BiondVax

 

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline. www.biondvax.com.

 

Contact Details

 

Company: Joshua E. Phillipson | +972 8 930 2529 | j.phillipson@biondvax.com

 

Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the timing of future clinical trials, and the therapeutic and commercial potential of NanoAbs. These forward-looking statements reflect management’s current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the risk that the therapeutic and commercial potential of NanoAbs will not be met; the risk of a delay in the preclinical and clinical data for NanoAbs, if any; the risk that BiondVax and EIB will not reach agreement with respect to the restructuring of the loan from European Investment Bank; the risk that BiondVax may not be able to secure additional capital on attractive terms, if at all; the risk that the European Investment Bank may accelerate the loans under its finance contract with BiondVax; risks relating to the COVID-19 (coronavirus) pandemic; BiondVax’s ability to acquire rights to additional product opportunities; BiondVax’s ability to enter into collaborations on terms acceptable to BiondVax or at all; timing of receipt of regulatory approval of BiondVax’s manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies, and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 25, 2022. BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.  

 

2

 

 

BALANCE SHEETS

In thousands, except share and per share data

 

               Convenience 
               Translation 
   December 31,   June 30,   June 30, 
   2021   2021   2022   2022 
   Audited   Unaudited   Unaudited 
   NIS   N I S   U.S. dollars 
CURRENT ASSETS:                
Cash and cash equivalents   54,036    39,883    39,499    11,285 
Other receivables   1,012    2,641    626    179 
                     
Total current assets   55,048    42,524    40,125    11,464 
                     
LONG TERM ASSETS:                    
                     
Property, plant and equipment   38,519    38,979    39,250    11,214 
Right-of-use assets   5,588    6,109    5,227    1,494 
Restricted cash   444    437    484    138 
Other long-term assets   -    -    485    139 
                     
Total non-current assets   44,551    45,525    45,446    12,985 
                     
Total assets   99,599    88,049    85,571    24,449 
                     
LIABILITIES AND SHAREHOLDERS’ EQUITY                    
CURRENT LIABILITIES:                    
                     
Trade payables   3,107    2,635    2,057    588 
Operating lease liabilities   773    764    857    245 
Loan from others   -    64,248    18,706    5,345 
Other payables   3,327    1,739    1,898    542 
                     
Total current liabilities   7,207    69,386    23,518    6,720 
                     
   LONG TERM LIABILITIES:                    
                     
Operating lease liabilities   5,712    6,047    5,536    1,582 
Loan from others   63,252    -    51,954    14,843 
Other payables   -    1,135    -    - 
Severance pay liability, net   95    95    95    27 
                     
Total long-term liabilities   69,059    7,277    57,585    16,452 
                     
SHAREHOLDERS’ EQUITY:                    
Ordinary shares of no par value: Authorized: 1,800,000,000 shares at June 30, 2022, (unaudited) June 30, 2021 (unaudited) and at December 31, 2021; Issued and outstanding: 747,153,064 shares at June 30, 2022 (unaudited), 573,285,824 shares at June 30, 2021 (unaudited) and 739,048,544 shares at December 31, 2021   (*)   (*)   (*)   (*)
Share premium   388,104    356,358    391,507    111,859 
Accumulated deficit   (364,771)   (344,972)   (387,039)   (110,582)
                     
Total Equity   23,333    11,386    4,468    1,277 
                     
Total liabilities and shareholders’ equity   99,599    88,049    85,571    24,449 

 

(*)Represents less than NIS\USD 1.

 

3

 

 

STATEMENTS OF COMPREHENSIVE LOSS
In thousands, except share and per share data

 

                       Convenience translation 
   Year ended
December 31,		   Three months ended
June 30,		   Six months ended
June 30,		   Six months ended
June 30,		 
   2021   2021   2022   2021   2022   2022 
   Audited   Unaudited   Unaudited 
   N I S   U.S. dollars 
   (In thousands, except per share data) 
Operating expenses:                              
Research and development, net of participations   10,341    1,900    6,495    4,653    10,148    2,900 
Marketing, general and administrative   24,528    7,002    4,286    11,007    8,919    2,548 
Other income   (40)   -    -    -    -    - 
                               
Total operating expenses   34,829    8,902    10,781    15,660    19,067    5,448 
                               
Operating loss   (34,829)   (8,902)   (10,781)   (15,660)   (19,067)   (5,448)
                              
Financial income   5,716    -    1,571    822    2,783    796 
Financial expense   (10,865)   (3,091)   (3,642)   (5,341)   (5,984)   (1,710)
                               
Net loss and total comprehensive loss  (39,978)   (11,993)   (12,852)   (20,179)   (22,268)   (6,362)
                               
Basic and diluted net loss per share   (0.07)   (0.03)   (0.02)   (0.04)   (0.03)   (0.01)
                               
Weighted average number of shares outstanding used to compute basic and diluted loss per share   564,575,9 67    573,205 ,607    746,898,6 71    552,140,0 30    745,817, 220    745,817,2 20   

 

The notes in the Company’s quarterly report are an integral part of the financial statements. The complete financial results are available in the Form 6-K to be filed with the Securities and Exchange Commission.

 

 

 

4

 

Exhibit 99.2

 

BIONDVAX PHARMACEUTICALS LTD.

 

INTERIM FINANCIAL STATEMENTS

 

AS OF JUNE 30, 2022

NIS IN THOUSANDS

 

UNAUDITED

 

INDEX

 

 

 

Page

   
Balance Sheets F-2 - F-3
   
Statements of Comprehensive Loss F-4
   
Statements of Changes in Shareholders’ Equity (Deficiency)   F-5 - F-7
   
Statements of Cash Flows F-8 - F-9
   
Notes to Interim Financial Statements F-10 - F-12

 

- - - - - - - - - - -

 

F-1

 

 

BIONDVAX PHARMACEUTICALS LTD.

 

BALANCE SHEETS

In thousands, except share and per share data

 

               Convenience 
               Translation 
               (Note 2) 
   December 31,   June 30,   June 30, 
   2021   2021   2022   2022 
   Audited   Unaudited   Unaudited 
   NIS   N I S   U.S. dollars 
CURRENT ASSETS:                
                 
Cash and cash equivalents   54,036    39,883    39,499    11,285 
Other receivables   1,012    2,641    626    179 
                     
Total current assets   55,048    42,524    40,125    11,464 
                     
LONG TERM ASSETS:                    
                     
Property, plant and equipment   38,519    38,979    39,250    11,214 
Right-of-use assets   5,588    6,109    5,227    1,494 
Restricted cash   444    437    484    138 
Other long-term assets   -    -    485    139 
                     
Total non-current assets   44,551    45,525    45,446    12,985 
                     
Total assets   99,599    88,049    85,571    24,449 

 

The accompanying notes are an integral part of the interim financial statements.

 

F-2

 

 

BIONDVAX PHARMACEUTICALS LTD.

 

BALANCE SHEETS

In thousands, except share and per share data

 

               Convenience 
               Translation 
               (Note 2) 
   December 31   June 30,   June 30, 
   2021   2021   2022   2022 
   Audited   Unaudited   Unaudited 
       N I S   U.S. dollars 
LIABILITIES AND SHAREHOLDERS’ EQUITY            
             
CURRENT LIABILITIES:                
                 
Trade payables   3,107    2,635    2,057    588 
Operating lease liabilities   773    764    857    245 
Loan from others   -    64,248    18,706    5,345 
Other payables   3,327    1,739    1,898    542 
                     
Total current liabilities   7,207    69,386    23,518    6,720 
                     
LONG TERM LIABILITIES:                    
                     
Operating lease liabilities   5,712    6,047    5,536    1,582 
Loan from others   63,252    -    51,954    14,843 
Other payables   -    1,135    -    - 
Severance pay liability, net   95    95    95    27 
                     
Total long-term liabilities   69,059    7,277    57,585    16,452 
                     
SHAREHOLDERS’ EQUITY:                    
Ordinary shares of no par value: Authorized: 1,800,000,000 shares at June 30, 2022, (unaudited) June 30, 2021 (unaudited) and December 31, 2021; Issued and outstanding: 747,153,064 shares at June 30, 2022 (unaudited), 573,285,824 shares at June 30, 2021 (unaudited) and 739,048,544 shares at December 31, 2021   
(*
)   
(*
)   
(*
)   
(*
)
Share premium   388,104    356,358    391,507    111,859 
Accumulated deficit   (364,771)   (344,972)   (387,039)   (110,582)
                     
Total Equity   23,333    11,386    4,468    1,277 
                     
Total liabilities and shareholders’ equity   99,599    88,049    85,571    24,449 

 

(*)Represents less than NIS\USD 1.

 

The accompanying notes are an integral part of the interim financial statements.

 

August 25, 2022            
Date of approval of the   Mark Germain   Amir Reichman   Uri Ben-Or
financial statements   Chairman of the Board   Chief Executive officer   Chief Financial Officer

 

F-3

 

 

BIONDVAX PHARMACEUTICALS LTD.

 

STATEMENTS OF COMPREHENSIVE LOSS

 

In thousands, except share and per share data

 

                      

Convenience
translation

(Note 2)

 
  

Year ended

December 31,

   Three months ended
June 30,		   Six months ended
June 30,		   Six months  
ended
June 30,		 
   2021   2021   2022   2021   2022   2022 
   Audited   Unaudited   Unaudited 
   N I S   U.S. dollars 
   (In thousands, except per share data)     
Operating expenses:                        
Research and development, net of participations   10,341    1,900    6,495    4,653    10,148    2,900 
Marketing, general and administrative   24,528    7,002    4,286    11,007    8,919    2,548 
Other income   (40)   
-
    
-
    
-
    
-
    
-
 
                               
Total operating expenses   34,829    8,902    10,781    15,660    19,067    5,448 
                               
Operating loss   (34,829)   (8,902)   (10,781)   (15,660)   (19,067)   (5,448)
              -                
Financial income   5,716    
-
    1,571    822    2,783    796 
Financial expense   (10,865)   (3,091)   (3,642)   (5,341)   (5,984)   (1,710)
                               
Net loss and total comprehensive loss   (39,978)   (11,993)   (12,852)   (20,179)   (22,268)   (6,362)
                               
Basic and diluted net loss per share
   (0.07)   (0.03)   (0.02)   (0.04)   (0.03)   (0.01)
                               
Weighted average number of shares outstanding used to compute basic and diluted loss per share
   564,575,967    573,205,607    746,898,671    552,140,030    745,817,220    745,817,220 

 

The accompanying notes are an integral part of the interim financial statements.

 

F-4

 

 

BIONDVAX PHARMACEUTICALS LTD.

 

STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIENCY)

In thousands, except share and per share data

 

   Share
capital		   Share
premium		  

Accumulated

deficit

  

Total

equity
(deficiency)

 
   Unaudited 
   NIS in thousands 
                 
Balance as of January 1, 2022   (*)    388,104    (364,771)   23,333 
                     
Total comprehensive loss   
-
    
-
    (22,268)   (22,268)
Issuance of shares, net   (*)    713    
-
    555 
Deferred issuance expenses        (148)          
Share-based compensation   
-
    2,848    
-
    2,848 
                     
Balance as of June 30, 2022   (*)    391,507    (387,039)   4,468 
                     
Balance as of June 30, 2022 (convenience translation into U.S. dollars (see Note 2))   (*)    111,859    (110,582)   1,277 

 

 

   Share
capital		   Share
premium		  

Accumulated

deficit

  

Total

deficiency

 
   Unaudited 
   NIS in thousands 
                 
Balance as of March 31, 2022   (*)    390,356    (374,187)   16,169 
                     
Total comprehensive loss   
-
    
-
    (12,852)   (12,852)
Deferred issuance expenses   (*)    (148)   -    (148)
Share-based compensation   -    1,299    -    1,299 
                     
Balance as of June 30, 2022   (*)    391,507    (387,039)   4,468 
                     
Balance as of June 30, 2022 (convenience translation into U.S. dollars (see Note 2))   (*)    111,859    (110,582)   1,277 

 

(*)Represents less than NIS\USD 1.

 

The accompanying notes are an integral part of the interim financial statements.

 

F-5

 

 

BIONDVAX PHARMACEUTICALS LTD.

 

STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIENCY)

In thousands, except share and per share data

 

   Share
capital		   Share
premium		  

Accumulated

deficit

  

Total

equity
(deficiency)

 
   Unaudited 
   NIS in thousands 
                 
Balance as of January 1, 2021   (*)    310,197    (324,793)   (14,596)
                     
Total comprehensive loss   -    -    (20,179)   (20,179)
Issuance of shares, net   
(*)
    42,129    -    42,129 
Share-based compensation   -    4,032    -    4,032 
                     
Balance as of June 30, 2021   (*)    356,358    (344,972)   11,386 
                     
Balance as of June 30, 2021 (convenience translation into U.S. dollars (see Note 2))   (*)    101,816    (98,563)   3,253 

 

   Share
capital		   Share
premium		  

Accumulated

deficit

  

Total

deficiency

 
   Unaudited 
   NIS in thousands 
                 
Balance as of March 31, 2021   
(*)
    353,783    (332,979)   20,804 
                     
Total comprehensive loss   -    -    (11,993)   (11,993)
Share-based compensation   -    2,575    -    2,575 
                     
Balance as of June 30, 2021   
(*)
    356,358    (344,972)   11,386 
                     
Balance as of June 30, 2021 (convenience translation into U.S. dollars (see Note 2))   (*)    101,816    (98,563)   3,253 

 

(*)Represents less than NIS\USD 1.

 

The accompanying notes are an integral part of the interim financial statements.

 

F-6

 

 

BIONDVAX PHARMACEUTICALS LTD.

 

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY)

In thousands, except share and per share data

 

   Share
capital		   Share premium   Accumulated
deficit		   Total
Deficiency		 
   Audited 
   NIS in thousands 
                 
Balance as of January 1, 2021   (*)    310,197    (324,793)   (14,596)
                     
Total comprehensive loss   -    -    (39,978)   (39,978)
Issuance of Ordinary shares, net of issuance costs   -    69,003    -    69,003 
Share-based compensation   -    8,904    -    8,904 
                     
Balance as of December 31, 2021   (*)    388,104    (364,771)   23,333 
                     
Balance as of December 31, 2021 (convenience translation into U.S. dollars (see Note 2))   (*)    110,886    (104,220)   6,666 

  

(*)Represents less than NIS\USD 1.

 

The accompanying notes are an integral part of the interim financial statements.

 

F-7

 

 

BIONDVAX PHARMACEUTICALS LTD.

 

STATEMENTS OF CASH FLOWS

In thousands, except share and per share data

 

                       Convenience
translation
(Note 2)		 
   Year ended
December 31,		   Three months ended
June 30,		   Six months ended
June 30,		   Six months
ended
June 30,		 
   2021   2021   2022   2021   2022   2022 
   Audited   Unaudited   Unaudited 
   N I S   U.S. dollars 
                         
Cash flows from operating activities:                        
Net loss   (39,978)   (11,993)   (12,852)   (20,179)   (22,268)   (6,362)
                               
Adjustments to reconcile net loss to net cash used in operating activities:                              
                               
Adjustments to profit and loss items:                              
Depreciation of property, plant and equipment and right-of-use assets   2,415    604    778    1,209    1,436    410 
Net financial expenses (income)   (930)   520    (1,334)   (471)   (2,108)   (602)
Capital gain   (40)   
-
    
-
    
-
    
-
    
-
 
Increase in liability with respect to loans from others   2,831    1,902    5,473    3,827    7,408    2,116 
Share-based compensation   8,904    2,575    1,299    4,032    2,848    814 
                               
    13,180    5,601    6,216    8,597    9,584    2,738 
Changes in asset and liability items:                              
Increase (decrease) in other receivables   162    (2,191)   (17)   (1,467)   376    107 
Increase (decrease) in trade payables   1,239    550    (2,045)   767    (1,050)   (300)
Increase (decrease) in short- and long-term other payables   946    99    (1,700)   493    (1,429)   (408)
                               
    2,347    (1,542)   (3,762)   (207)   (2,103)   (601)
Cash paid and received during the year for:                              
Interest paid   (33)   24    (8)   15    (14)   (4)
                               
    (33)   24    (8)   15    (14)   (4)
                               
Net cash flows used in operating activities   (24,484)   (7,910)   (10,406)   (11,774)   (14,801)   (4,229)

 

(*)Represents an amount lower than NIS\USD 1.

 

The accompanying notes are an integral part of the interim financial statements.

 

F-8

 

 

BIONDVAX PHARMACEUTICALS LTD.

 

STATEMENTS OF CASH FLOWS

In thousands, except share and per share data

 

                      

Convenience translation

(Note 2)

 
  

Year ended
December 31,

 
 

Three months ended

June 30,

  

Six months ended

June 30,

  

Six months

ended

June 30,

 
   2021   2021   2022   2021   2022   2022 
   Audited   Unaudited   Unaudited 
   N I S   U.S. dollars 
         
Cash Flows from Investing Activities:                        
Purchase of property and equipment   (430)   (106)   (44)   (128)   (1,700)   (486)
Proceeds from sale of property and equipment   40    
-
    
-
    
-
    
-
    
 
 
 Increase (decrease) in other long term assets   29    (1)   (40)   36    (40)   (11)
                               
Net cash used in investing activities   (361)   (107)   (84)   (92)   (1,740)   (497)
                               
Cash Flows from Financing Activities:                              
                               
Repayment of operating lease liabilities   (1,220)   (317)   (320)   (623)   (633)   (181)
Deferred issuance expenses   
-
         (148)        (148)   (42)
Proceeds from exercise of warrants to public   
-
    
-
    
-
    42,129    
-
    
-
 
Proceeds from issuance of shares, net of issuance costs   69,003    
-
    
-
    
-
    
-
    
-
 
                               
Net cash provided by (used in) financing activities   67,783    (317)   (468)   41,506    (781)   (223)
                               
Exchange differences on balances of cash and cash equivalents   1,677    (360)   1,571    822    2,785    796 
                               
Increase (decrease) in cash and cash equivalents   44,615    (8,694)   (9,347)   30,462    (14,537)   (4,142)
Balance of cash and cash equivalents at the beginning of the period   9,421    48,577    48,886    9,421    54,036    15,439 
                               
Balance of cash and cash equivalents at the end of the period   54,036    39,883    39,499    39,883    39,499    11,297 
                               
Non cash financing activities                              
                               
Right-of-use asset recognized with corresponding lease liability   249    
-
    107    
-
    107    31 
Intangible asset        
-
    
-
    
-
    485    139 

 

The accompanying notes are an integral part of the interim financial statements.

 

F-9

 

 

BIONDVAX PHARMACEUTICALS LTD.

 

NOTES TO INTERIM FINANCIAL STATEMENTS

In thousands, except share and per share data

 

NOTE 1: GENERAL

 

a.BiondVax Pharmaceuticals Ltd. ("the Company") is focused on developing and ultimately commercializing products for prevention and treatment of infectious diseases and related illnesses. The Company was incorporated on July 21, 2003 in Israel, and started its activity on March 31, 2005. The Company's principal executive offices and main laboratory are located at Jerusalem BioPark, 2nd floor, Hadassah Ein Kerem Campus, Jerusalem, Israel, next to Hadassah University Hospitals and Hebrew University’s Medical School.

 

b.On May 15, 2015, the Company completed a public offering of securities in the United States.

 

c.On March 28, 2017, the Company received an approval from the Investment Center of the Ministry of Economy and Industry of the State of Israel, for a grant (the “Grant") representing 20% of a NIS 20,000 budget to be utilized towards the construction of a factory for the production of Phase 3 and commercial batches of M-001, the Company's former influenza vaccine candidate. The receipt of the Grant was subject to certain terms and conditions, including those outlined under the Israeli Encouragement of Capital Investment Law, 1959. The terms and conditions included, inter alia, the following: (a) at least 24% of the investments in the planned manufacturing facility's fixed assets would be financed by additional share capital; (b) the Company would maintain its intellectual property and manufacturing facility in Israel for a period of at least 10 years.

 

Following the failure of M-001 in Phase 3 clinical trials, BiondVax reapplied for disbursement of the Grant in light of its new agreements with Max Planck Institute for Multidisciplinary Sciences in Göttingen together with University Medical Center Göttingen. In July 2022, the Investment Center of the Ministry of Economy and Industry informed the Company that (i) the disbursement was not approved, due to the early stage of the Company’s NanoAb program and (ii) the Company may reapply for disbursement in March 2023, conditioned on the Company demonstrating meeting certain milestones related to the development of its NanoAb program. The Company intends to appeal the decision.

 

d.On October 23, 2020, the Company announced Phase 3 clinical trial results of its M-001 universal vaccine product. The results did not demonstrate a statistically significant difference between the vaccinated group and the placebo group in reduction of flu illness and severity. Therefore, the study failed to meet both the primary and secondary efficacy endpoints. However, the study’s primary safety endpoint was met.

 

e.On December 22, 2021, the Company signed definitive agreements with the Max Planck Society (“MPG”), the parent organization of the Max Planck Institute for Biophysical Chemistry, and the University Medical Center Göttingen (“UMG”), both in Germany, to enter into a strategic collaboration for the development and commercialization of innovative Covid-19 NanoAbs, effective from January 1, 2022. The agreements provide for an upfront payment, development and sales milestones and royalties based on sales and sharing of sublicense revenues.

 

In accordance with the agreements, the Company issued 150,000 ADSs at no cost to MPG as an upfront payment for the license. The ADS are restricted for a period of three years. The company evaluated the fair value of the license at $153. The fair value was calculated by an independent valuation, at a discount rate of 31% under the following principles:

 

Stock price   1.48 
Variance   150%
Risk free interest   1%

 

F-10

 

 

BIONDVAX PHARMACEUTICALS LTD.

 

NOTES TO INTERIM FINANCIAL STATEMENTS

In thousands, except share and per share data

 

NOTE 1: GENERAL (Cont.)

 

On March 23, 2022, the Company executed an additional research collaboration agreement with MPG and UMG covering development and commercialization of NanoAbs for several other disease indications with large market sizes that leverage their unique binding affinity, stability at high temperatures, and potential for more effective and convenient routes of administration. These targets are the basis for validated and currently marketed monoclonal antibodies, including for conditions such as psoriasis, asthma, macular degeneration, and psoriatic arthritis.

 

f.On March 23, 2022, the Company granted 170,132 RSUs to officers and employees. The fair value of the grants was NIS 753,084 ($233,081) and the RSUs vest in three years.

 

g.On May 31, 2022, the Company granted 15,500 RSUs to employees. The fair value of the grants was NIS 69,330 ($20,770) and the RSUs vest in three years.

 

h.In the six months ended June 30, 2022, the Company incurred a loss of NIS 22,268 (6,362) and negative cash flows from operating activities of NIS 14,802 ($4,229), and it had an accumulated deficit of NIS 387,039 ($110,583) as of that date.

 

In the future, the Company may raise additional capital from external sources in order to continue the longer-term efforts contemplated under its business plan. The Company expects to continue incurring losses for the foreseeable future and may need to raise additional capital to pursue its product development initiatives, to penetrate markets for the sale of our Company product candidates and continue operations as presently maintained. The Company cannot provide any assurance that it will raise additional capital. Management believes that the Company has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company has not secured any commitment for new financing at this time, nor can the Company provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s efforts to commercialize its products, which is critical to the realization of the Company’s business plan and its future operations.

 

The Company’s management and Board of Directors are of the opinion that its current financial resources will be sufficient to continue the development of the Company’s products for at least the next twelve months.

 

NOTE 2: CONVENIENCE TRANSLATION INTO U.S. DOLLARS

 

The financial statements as of June 30, 2022 and for the six months then ended have been translated into dollars using the representative exchange rate as of that date ($ 1 = NIS 3.5). The translation was made solely for the convenience of the reader. The amounts presented in these financial statements should not be construed to represent amounts receivable or payable in dollars or convertible into dollars, unless otherwise indicated in these statements.

 

F-11

 

 

BIONDVAX PHARMACEUTICALS LTD.

 

NOTES TO INTERIM FINANCIAL STATEMENTS

In thousands, except share and per share data

 

NOTE 3: SIGNIFICANT ACCOUNTING POLICIES

 

These financial statements have been prepared in a condensed format as of June 30, 2022, and for the three and six months then ended ("interim financial statements"). These financial statements should be read in conjunction with the Company's annual financial statements as of December 31, 2021, and for the year then ended and accompanying notes ("annual financial statements").

 

Basis of preparation of the interim financial statements

 

The interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles for the preparation of financial statements for interim periods, as prescribed in IAS 34, "Interim Financial Reporting", and in accordance with the disclosure requirements of Chapter D of the Securities Regulations (Periodic and Immediate Reports), 1970.

 

The significant accounting policies and methods of computation adopted in the preparation of the interim financial statements are consistent with those followed in the preparation of the Company's annual financial statements.

 

NOTE 4: SUBSEQUENT EVENTS

 

On August 10, 2022, the company received approval by the European Investment Bank for the new terms of its outstanding €24 million loan to the Company.

 

The new terms include:

 

●An extension of the maturity dates from 2023 (€20 million) and 2024 (€4 million) until December 2027.

 

●Interest on the Loan will begin to accrue starting January 1, 2022, at an annual rate of 7%. The interest payments will be deferred until the new maturity date and will be added to the principal balance at the end of each year during the loan period.

 

●$900 thousand (NIS 3,500 thousand) will be paid by BiondVax shortly after the execution of the relevant amendment letter with the EIB. This amount will be applied to reduce the outstanding Loan. Going forward 10% of any capital raises until maturity will be used to further repay the Loan principal including any outstanding accrued interest.

 

●When the company sales exceed €5 million, 3% of the topline revenues will be paid to the EIB as royalties until the EIB receives (from the Loan repayment, inter alia the interest and the royalties) the higher of (i) a total of 2.8 times the original €24 million principal (as provided in the original Loan agreement) and (ii) 20% IRR on the principal.

 

●In case the company decides to discharge all liabilities under the finance contract inter alia payments of the variable remuneration, the company would need to repay to the EIB an indemnity amount in addition to the Loan principle and the accrued interest. The indemnity will be calculated such that the EIB receives an additional payment equal to the greater of (i) the prepayment amount (i.e. twice the prepayment amount in the aggregate) and (ii) the amount required to realize 20% IRR on the prepayment amount at the time of prepayment.

 

- - - - - - - - - - -

 

 

F-12

 

 

0.01 0.02 0.03 0.03 0.04 0.07 564575967 573205607 746898671 552140030 745817220 745817220 This Amendment No. 1 to the Report on Form 6-K, originally filed with the Securities and Exchange Commission on August 25, 2022, is being filed solely for the purposes of furnishing unaudited interim condensed consolidated financial statements as of June 30, 2022 and incorporating certain exhibits into registration statements of the registrant. true --12-31 Q2 2022 2022-06-30 6-K/A 0001611747 BIONDVAX PHARMACEUTICALS LTD. 0001611747 2022-01-01 2022-06-30 0001611747 2021-12-31 0001611747 2021-06-30 0001611747 2022-06-30 0001611747 2021-01-01 2021-12-31 0001611747 2021-04-01 2021-06-30 0001611747 2022-04-01 2022-06-30 0001611747 2021-01-01 2021-06-30 0001611747 bvxv:ClasseOfShareCapitalMember 2021-12-31 0001611747 ifrs-full:SharePremiumMember 2021-12-31 0001611747 ifrs-full:RetainedEarningsMember 2021-12-31 0001611747 bvxv:ClasseOfShareCapitalMember 2022-01-01 2022-06-30 0001611747 ifrs-full:SharePremiumMember 2022-01-01 2022-06-30 0001611747 ifrs-full:RetainedEarningsMember 2022-01-01 2022-06-30 0001611747 bvxv:ClasseOfShareCapitalMember 2022-06-30 0001611747 ifrs-full:SharePremiumMember 2022-06-30 0001611747 ifrs-full:RetainedEarningsMember 2022-06-30 0001611747 bvxv:ClasseOfShareCapitalMember 2022-03-31 0001611747 ifrs-full:SharePremiumMember 2022-03-31 0001611747 ifrs-full:RetainedEarningsMember 2022-03-31 0001611747 2022-03-31 0001611747 bvxv:ClasseOfShareCapitalMember 2022-04-01 2022-06-30 0001611747 ifrs-full:SharePremiumMember 2022-04-01 2022-06-30 0001611747 ifrs-full:RetainedEarningsMember 2022-04-01 2022-06-30 0001611747 bvxv:ClasseOfShareCapitalMember 2020-12-31 0001611747 ifrs-full:SharePremiumMember 2020-12-31 0001611747 ifrs-full:RetainedEarningsMember 2020-12-31 0001611747 2020-12-31 0001611747 ifrs-full:RetainedEarningsMember 2021-01-01 2021-06-30 0001611747 bvxv:ClasseOfShareCapitalMember 2021-01-01 2021-06-30 0001611747 ifrs-full:SharePremiumMember 2021-01-01 2021-06-30 0001611747 ifrs-full:SharePremiumMember 2021-06-30 0001611747 ifrs-full:RetainedEarningsMember 2021-06-30 0001611747 bvxv:ClasseOfShareCapitalMember 2021-06-30 0001611747 bvxv:ClasseOfShareCapitalMember 2021-03-31 0001611747 ifrs-full:SharePremiumMember 2021-03-31 0001611747 ifrs-full:RetainedEarningsMember 2021-03-31 0001611747 2021-03-31 0001611747 ifrs-full:RetainedEarningsMember 2021-04-01 2021-06-30 0001611747 ifrs-full:SharePremiumMember 2021-04-01 2021-06-30 0001611747 ifrs-full:RetainedEarningsMember 2021-01-01 2021-12-31 0001611747 ifrs-full:SharePremiumMember 2021-01-01 2021-12-31 0001611747 2017-03-28 0001611747 2017-03-01 2017-03-28 0001611747 2022-03-23 0001611747 2022-08-10 0001611747 bvxv:NonadjustingEventsAfterReportingPeriodMember 2023-01-01 2023-12-31 0001611747 bvxv:NonadjustingEventsAfterReportingPeriodMember 2024-01-01 2024-12-31 0001611747 bvxv:NonadjustingEventsAfterReportingPeriodMember 2021-10-19 iso4217:ILS iso4217:USD iso4217:USD xbrli:shares xbrli:shares iso4217:ILS xbrli:shares xbrli:pure iso4217:EUR